Skip to main content
$0.056 -0.002 (-3.45%)

High

$0.06

Low

$0.06

Trades

69

Turnover

$115,211

Volume

1,984,515
30 June 2023 at 3:59pm
If you were already registered, log in here.

Short Interest

ASIC data, 13 Nov 2026

% Shorted

0.55% 0.04
vs 0.59% prior report

Most Shorted Rank

317th
of 723 shorted ASX stocks

Peak Short

1.09%
Sep 2026

Days to Cover

1.3
at 50d avg vol
Subject
PYC Ann: Application for quotation of securities - PYC

PYC Ann: New U.S. Headquarters, and Residency at JLABS

PYC Ann: Second Drug Program Progressing Towards Human Trials

PYC Ann: Trading Halt

PYC Ann: Evercore ISI GenomeRx Emerging Therapeutic Company Day

PYC Ann: SECOND DRUG PROGRAM - EFFICACY DATA IN PATIENT CELL MODELS

PYC Ann: PYC Invited to Present at ARVO 2021 Annual Meeting

PYC Ann: Set To Announce Efficacy Results For Second Drug Program

PYC Ann: March 2021 Quarterly Report and Cashflow

PYC Ann: Corporate Presentation April 2021

PYC Ann: April Investor Call Presentation

PYC Ann: Preclinical Data - Superior PPMO Delivery to the Brain

PYC Ann: Quarterly Investor Call - 15th April 2021

PYC Ann: Appendix 3X - Initial Director's Interest Notice

PYC Ann: Appendix 3G - Issue of Options

PYC Ann: PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board

PYC Ann: Director Retirement

PYC Ann: Appendix 3G - Issue of Options

PYC Ann: Initial Director's Interest Notice

PYC Ann: Participation in SVB Leerink Biopharma Private Co Connect

PYC Ann: PYC Appoints US Biotech Veteran to its Board of Directors

PYC Ann: Lead Investigational Drug Demonstrates Key Improvement

PYC Ann: Half Year Accounts and Appendix 4D

PYC Ann: PYC Expands US Executive Leadership Team

PYC Ann: Progress US Clinical Stage Company and Corporate Objectives

PYC Ann: Change of Director's Interest Notice

PYC Ann: PYC to Participate in RNA Discussion - CEO BIO Conference

PYC Ann: Quarterly Activities Report and Appendix 4C

PYC Ann: ICR Conference Presentation

PYC Ann: PYC to Present at ICR Westwicke Conference

PYC Ann: Appendix 3G

PYC Ann: Initial Director's Interest Notice

PYC Ann: Visual Evidence of Lead Drugs Efficacy

PYC Ann: Letter to Shareholders from the US CEO

PYC Ann: Appointment of Chief Executive Officer in the United States

PYC Ann: PYC to Present at the Evercore ISI Conference

PYC Ann: Change in substantial holding

PYC Ann: Retail Entitlement Offer Share Issue and Appendix 2A

PYC Ann: Completion of Retail Entitlement Offer

PYC Ann: Final Director's Interest Notice

PYC Ann: New Constitution

PYC Ann: Results of Annual General Meeting

PYC Ann: AGM Chairman's Address and CEO Presentation

PYC Ann: Grants Awarded to Support Clinical Progression of Lead Drug

PYC Ann: Notice under Section 708(A)

PYC Ann: Change of Director's Interest Notice x 2

PYC Ann: Change in substantial holding

PYC Ann: Appendix 2A

PYC Ann: Review of Activities and Appendix 4C

PYC Ann: Dispatch of Notice to Ineligible Retail Shareholders

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
RAC
TLX
S88
MAV
RDO $30m raise
ABC $5m raise
RGS
MBM
ATW $7.5m raise